SCHEMBL11895688

SCHEMBL11895688

O[C@]12CCCC[C@@H]1CCCC2Nc1cccc(-c2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 8/20 0.59
MGLL Q99685 2/20 0.41
FAAH O00519 1/20 0.41
POLB P06746 2/20 0.38
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ESR1 P03372 1/20 0.35
PGR P06401 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TRPC5 Q9UL62 1/20 0.35
KDM4E B2RXH2 1/20 0.34
NR5A2 O00482 1/20 0.34
NR5A1 Q13285 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11954714 0.88 TRPA1 (0.71) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11971137 0.88 TRPA1 (0.71) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11895444 0.88 TRPA1 (0.71) TRPA1ESR1PGRHTR2ASLC6A3
SCHEMBL11966306 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL11895629 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL11895419 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL11967558 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL10827 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL3580 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1
SCHEMBL14599 0.88 TRPA1 (0.74) TRPA1POLBHPGDTSHRESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US claimed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP claimed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US claimed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 TRPA1 1/4885MGLL 2471/4885FAAH 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.